High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity

Gwendalyn D. King, A. K.M.Ghulam Muhammad, Weidong Xiong, Kurt M. Kroeger, Mariana Puntel, Daniel Larocque, Donna Palmer, Philip Ng, Pedro R. Lowenstein, Maria G. Castro

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Gene therapy is proposed as a novel therapeutic strategy for treating glioblastoma multiforme (GBM), a devastating brain cancer. In the clinic, antivector immune responses pose formidable challenges. Herein we demonstrate that high-capacity adenovirus vectors (HC-Ads) carrying the conditional cytotoxic gene herpes simplex virus type 1-thymidine kinase (TK) induce tumor regression and long-term survival in an intracranial glioma model, even in the presence of systemic antiadenovirus immunity, as could be encountered in patients. First-generation Ad-TK failed to elicit tumor regression in this model. These results pave the way for implementing HC-Ad-TK-mediated gene therapy as a powerful adjuvant for treating GBM.

Original languageEnglish (US)
Pages (from-to)4680-4684
Number of pages5
JournalJournal of Virology
Volume82
Issue number9
DOIs
StatePublished - May 2008
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Fingerprint

Dive into the research topics of 'High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity'. Together they form a unique fingerprint.

Cite this